In 56 selected lung cancer patients from the LAVA database harboring MET fusions, 38 patients had primary MET fusions and 18 patients acquired MET fusions after developing resistance to EGFR/ALK-TKIs, as shown in Table 3. This evidence concerns the gene ALK and lung cancer.